Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.

Hematol Oncol · 2025 · PMC12064212 · PMID 40344674

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As best response, ≥ MR3 was achieved by 63.7% of intolerant patients (27.3% in MR3 and 36.4% in DMR) versus 45.5% resistant (15.9% in MR3 and 29.6% in DMR), resulting in an OR of 2.10 that showed a trend to reach at least MR3 response in intolerant versus resistant patients, although not statistically significant (95% CI: 0.83–5.29, p = 0.116). 3.4.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.